OBJECTIVE: To estimate the cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP). METHODS: In two previous IPTi trials in Ifakara (United Republic of Tanzania) and Manhiça (Mozambique), SP was administered three times to infants before 9 months of age through the Expanded Programme on Immunization. Based on the efficacy results of the intervention and on malaria incidence in the target population, an estimate was made of the number of clinical malaria episodes prevented. This number and an assumed case-fatality rate of 1.57% were used, in turn, to estimate the number of disability-adjusted life years (DALY) averted and the number of deaths averted. The cost of the intervention, including start-up and recurrent costs, was then assessed on the basis of these figures. FINDINGS: The cost per clinical episode of malaria averted was US$ 1.57 (range: US$ 0.8-4.0) in Ifakara and US$ 4.73 (range: US$ 1.7-30.3) in Manhiça; the cost per DALY averted was US$ 3.7 (range: US$ 1.6-12.2) in Ifakara and US$ 11.2 (range: US$ 3.6-92.0) in Manhiça; and the cost per death averted was US$ 100.2 (range: US$ 43.0-330.9) in Ifakara and US$ 301.1 (range: US$ 95.6-2498.4) in Manhiça. CONCLUSION: From the health system and societal perspectives, IPTi with SP is expected to produce health improvements in a cost-effective way. From an economic perspective, it offers good value for money for public health programmes.
OBJECTIVE: To estimate the cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP). METHODS: In two previous IPTi trials in Ifakara (United Republic of Tanzania) and Manhiça (Mozambique), SP was administered three times to infants before 9 months of age through the Expanded Programme on Immunization. Based on the efficacy results of the intervention and on malaria incidence in the target population, an estimate was made of the number of clinical malaria episodes prevented. This number and an assumed case-fatality rate of 1.57% were used, in turn, to estimate the number of disability-adjusted life years (DALY) averted and the number of deaths averted. The cost of the intervention, including start-up and recurrent costs, was then assessed on the basis of these figures. FINDINGS: The cost per clinical episode of malaria averted was US$ 1.57 (range: US$ 0.8-4.0) in Ifakara and US$ 4.73 (range: US$ 1.7-30.3) in Manhiça; the cost per DALY averted was US$ 3.7 (range: US$ 1.6-12.2) in Ifakara and US$ 11.2 (range: US$ 3.6-92.0) in Manhiça; and the cost per death averted was US$ 100.2 (range: US$ 43.0-330.9) in Ifakara and US$ 301.1 (range: US$ 95.6-2498.4) in Manhiça. CONCLUSION: From the health system and societal perspectives, IPTi with SP is expected to produce health improvements in a cost-effective way. From an economic perspective, it offers good value for money for public health programmes.
Authors: M Alonzo González; C Menéndez; F Font; E Kahigwa; J Kimario; H Mshinda; M Tanner; X Bosch-Capblanch; P L Alonso Journal: Bull World Health Organ Date: 2000 Impact factor: 9.408
Authors: D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: David Schellenberg; Clara Menendez; John Aponte; Caterina Guinovart; Hassan Mshinda; Marcel Tanner; Pedro Alonso Journal: Trop Med Int Health Date: 2004-01 Impact factor: 2.622
Authors: Julius J Massaga; Andrew Y Kitua; Martha M Lemnge; Jumaa A Akida; Lincoln N Malle; Anita M Rønn; Thor G Theander; Ib C Bygbjerg Journal: Lancet Date: 2003-05-31 Impact factor: 79.321
Authors: Fatuma Manzi; Guy Hutton; Joanna Schellenberg; Marcel Tanner; Pedro Alonso; Hassan Mshinda; David Schellenberg Journal: BMC Health Serv Res Date: 2008-07-31 Impact factor: 2.655
Authors: Ilona Carneiro; Lucy Smith; Amanda Ross; Arantxa Roca-Feltrer; Brian Greenwood; Joanna Armstrong Schellenberg; Thomas Smith; David Schellenberg Journal: Bull World Health Organ Date: 2010-05-10 Impact factor: 9.408
Authors: Joanna R M Armstrong Schellenberg; Kizito Shirima; Werner Maokola; Fatuma Manzi; Mwifadhi Mrisho; Adiel Mushi; Hassan Mshinda; Pedro Alonso; Marcel Tanner; David M Schellenberg Journal: Am J Trop Med Hyg Date: 2010-05 Impact factor: 2.345
Authors: Alassane Dicko; Sidy O Toure; Mariam Traore; Issaka Sagara; Ousmane B Toure; Mahamadou S Sissoko; Alpha T Diallo; Christophe Rogier; Roger Salomon; Alexandra de Sousa; Ogobara K Doumbo Journal: BMC Public Health Date: 2011-07-18 Impact factor: 3.295
Authors: Lesong Conteh; Elisa Sicuri; Fatuma Manzi; Guy Hutton; Benson Obonyo; Fabrizio Tediosi; Prosper Biao; Paul Masika; Fred Matovu; Peter Otieno; Roly D Gosling; Mary Hamel; Frank O Odhiambo; Martin P Grobusch; Peter G Kremsner; Daniel Chandramohan; John J Aponte; Andrea Egan; David Schellenberg; Eusebio Macete; Laurence Slutsker; Robert D Newman; Pedro Alonso; Clara Menéndez; Marcel Tanner Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: Matthew Cairns; Azra Ghani; Lucy Okell; Roly Gosling; Ilona Carneiro; Francis Anto; Victor Asoala; Seth Owusu-Agyei; Brian Greenwood; Daniel Chandramohan; Paul Milligan Journal: PLoS One Date: 2011-04-20 Impact factor: 3.240